Safety and efficacy of long-term use of sodium oxybate for narcolepsy with cataplexy in routine clinical practice

Panagis Drakatos, Dimosthenis Lykouras, Grainne D’Ancona, Sean Higgins, Nadia Gildeh, Raluca Macavei, Ivana Rosenzweig, Joerg Steier, Adrian J. Williams, Rexford Muza, Brian D. Kent, Guy Leschziner

Article history:
Received 9 February 2017
Received in revised form 10 March 2017
Accepted 15 March 2017
Available online 6 May 2017

Keywords:
Sodium oxybate
Narcolepsy
Cataplexy
Adverse effects

1. Introduction

Narcolepsy is a chronic neurological disorder causing dysregulation of sleep and wakefulness, with a prevalence of approximately 1 in 3000 [1]. It is characterised by excessive daytime sleepiness (EDS), cataplexy, hypnagogic/hypnopompic hallucinations, sleep paralysis and disturbed sleep [2].

There is no cure for narcolepsy at present, and current treatment focuses on symptom control. A reduction in daytime sleepiness is achievable with medications that increase wakefulness, including wake promoters such as modafinil, amphetamines, and methylphenidate, while cataplexy is typically controlled through the use of antidepressant drugs which suppress Rapid Eye Movement sleep [3–6].

Sodium oxybate, the sodium salt of gamma-hydroxybutyrate (GHB), an endogenous metabolite of gamma-aminobutyric acid (GABA), is a central nervous system depressant. It is indicated for the treatment of both cataplexy and EDS associated with narcolepsy [7]. Its mode of action is uncertain, but it may involve stimulation of...
GABA-B receptors [8]. Sodium oxybate is rapidly absorbed and metabolised, having a mean elimination half-life of 90–120 min. It is currently authorized by the European Medicines Agency to treat narcolepsy with cataplexy in adults, and by the US Food and Drug Administration (FDA) to treat cataplexy in patients with narcolepsy, with an “expanded indication” for the treatment of EDS [3,9].

Existing data regarding the tolerability and efficacy of sodium oxybate in narcolepsy originate from prospective drug trials [10–13]. We aimed to analyse the use of sodium oxybate in routine European clinical practice, where sodium oxybate is reserved for a sub-group of patients with narcolepsy with cataplexy, patients more likely to be on multiple other therapies with a more severe phenotype.

2. Materials and methods

We performed a retrospective study assessing patients attending a tertiary referral sleep disorders centre. All patients diagnosed with narcolepsy with cataplexy and initiated on sodium oxybate between 2009 and 2015 were included. A full medical history, sleep history, sleep study results and demographics were recorded for all patients. The reduction of Epworth Sleepiness Scale (ESS) score (ΔESS) and of cataplexy events expressed in events/week (Δcataplexy) were recorded from patients’ notes and relevant diaries, as the differences between ESS and cataplexy events before sodium oxybate initiation (baseline) and after a dose of sodium oxybate providing optimal clinical effect was achieved (final).

Due to the nature of the study and the limitations that apply in the UK for sodium oxybate treatment eligibility, patients could already be on other drugs for narcolepsy (stimulants or/and anti-cataplectic agents). According to policies in place for prescribing of sodium oxybate within the UK National Health Service (NHS), patients were only eligible for this drug if they had tried at least two stimulants and/or two anti-cataplectic agents, and remained symptomatic with an ESS ≥ 17 or with an average 21 cataplectic events per week.

All the patients in this study were initially treated with oral sodium oxybate 4.5 g/night, given as two equally divided doses 2.5–4 h apart and titrated, according to response, up to a maximum dose of up to 9 g/night in two doses of 4.5 g each, with dose adjustments every two weeks, as stipulated in the approved prescribing protocol. Any subsequent reduction or elimination of other drugs for narcolepsy was recorded. Appropriate approval from the institutional review board on human research was obtained (project number 4641).

3. Diagnosis

The diagnosis of narcolepsy with cataplexy was made according to the International Classification of Sleep Disorders-2 (ICSD-2) criteria of the American Academy of Sleep Medicine (AASM), due to the retrospective nature of the study [14].

4. Outcomes analysis

Safety and tolerability were evaluated based on reported side effects (SEs), without a pre-established list of SEs, during every follow-up visit after initiation of sodium oxybate. SEs were categorized into groups: namely infections, psychiatric, neurological, gastrointestinal, general, sleep disorders and cardiological SEs, in keeping with those listed in the summary of product characteristics [15]. Reports from patients’ notes of mood changes throughout the day, which could vary from elevated mood to anger to sadness within a few hours, and changes in mood clearly out of proportion to circumstances which could also cause impairment in functioning, were grouped under the term mood swings. Psychotic symptoms were confirmed by formal psychiatric assessment and were made according to the Diagnostic and Statistical Manual of Mental Disorders fifth edition (DSM-V) criteria [16].

5. Statistics

Results are reported as mean ± SD if not otherwise indicated. Following testing for normality, comparison between groups was performed using independent-samples Mann–Whitney U test. Spearman product correlation coefficient was used for correlations between continuous and nominal variables and Chi Square with Cramer’s V product for correlations between nominal variables. Comparison of baseline and final ESS and cataplexy events within patients was calculated using related-samples Wilcoxon Signed-Ranks Test. A multiple stepwise linear regression analysis was performed to identify which variables most satisfactorily explained ΔESS and Δcataplexy in our patients. Binary regression analysis with forward stepwise method was applied in three prediction models: 1) to predict which patients exhibited a reduction of other drugs (wake promoters, stimulants or/and anti-cataplectic agents) due to sodium oxybate initiation, 2) which experienced any SEs secondary to sodium oxybate, and 3) which patients had to discontinue the drug due to SEs. Statistical significance was defined as p < 0.05. IBM SPSS Statistics V24.0 (SPSS, Chicago, IL/USA) was used for all statistical analysis.

6. Results

6.1. Efficacy

A total of 90 patients with narcolepsy with cataplexy, aged 42.5 ± 14.9 years, were prescribed sodium oxybate during the study period, with a total of 3116 patient-months of drug exposure, and a median 35.5 months (interquartile range 11.0–54.0) of follow up time (FU) (Table 1).

Sodium oxybate significantly reduced the ESS (ΔESS = 4.3 ± 4.4, p < 0.0001). The most common optimal dose of sodium oxybate was 9 g/night (31/90, 33.3%), but many patients were treated with lower doses (22.2% required 4.5 g/night, 22% 6 g/night, and 18% 7.5 g/night).

The improvement in ESS (ΔESS) correlated with higher final dose of the drug (r = 0.389, p < 0.001), but no correlation was found with age and BMI. A stepwise regression analysis was performed for predictors of ΔESS in the group of patients that did not discontinue sodium oxybate due to side effects or lack of efficacy. Age, BMI, Body Mass Index; ESS, Epworth Sleepiness Scale score. *: Baseline and final terms use as reference points the status before sodium oxybate initiation and after optimum dose of sodium oxybate had been achieved, respectively. FU, follow-up is reported as median; IQR, interquartile range. The term combination treatment refers to stimulants or wake promoters and anti-cataplectic agents.

Table 1
Demographics, baseline characteristics and treatment of the studied cohort.

| Parameters (n = 90) | Mean ± SD |
|---------------------|-----------|
| Age (years)         | 42.5 ± 14.9 |
| Gender (M/F)        | 38/52     |
| BMI (kg/m²)         | 30.1 ± 7.8  |
| *ESS baseline       | 18.9 ± 3.4  |
| *ESS final          | 14.5 ± 5.1  |
| *Cataplexy events/week baseline | 26.2 ± 22.7 |
| *Cataplexy events/week final | 4.4 ± 10.8 |
| Patients on stimulants or wake promoters, n (%) | 36 (40) |
| Patients on anti-cataplectic agents, n (%) | 7 (7.8) |
| Patients on combination treatment, n (%) | 44 (48.9) |
| Patients on no treatment, n (%) | 3 (3.3) |
| FU time (months)    | 35.5 (IQR 11.0–54.0) |
BMI, gender, number of other concomitant drugs, reduction of other drug dosages, final sodium oxybate dose, and baseline ESS were added as independent variables. Patients who were sleepier at baseline were more likely to experience the greatest reduction in ESS (n = 61, F = 4.876, R = 3.23, adjusted R² = 0.083, p = 0.033). No difference was found between genders with regard to age, BMI, baseline ESS, sodium oxybate final dose and ΔESS (p > 0.05).

A similar analysis was performed assessing the efficacy of sodium oxybate in controlling cataplexy, demonstrating a significant reduction in frequency of cataplectic events (Δcataplexy 21.8 ± 18.5 events/week; p < 0.0001). There was no correlation between age, BMI, final dose of sodium oxybate, and Δcataplexy. A stepwise regression analysis assessing predictors of Δcataplexy, using the same variables outlined above, demonstrated that only the baseline cataplexy frequency predicted reduction in cataplexy events (n = 61, F = 137.602, R = 0.898, adjusted R² = 0.801, p < 0.0001). There was no difference between genders in the number of baseline cataplexy events or in Δcataplexy (p > 0.05).

Sixty-one patients were successfully treated with sodium oxybate (61/90, 67.7%) and all patients except for one were on other drugs for narcolepsy. Twenty of those (32.8%) were on one or more stimulant medication, 37 (50.7%) on a combination of stimulant and anti-cataplectic agents, and three (4.5%) on an anti-cataplectic agent. The administration of sodium oxybate led to a reduction in dosage of other drugs in 56% (34/60) of patients, of which the majority remained on combined treatment (70.6%), but in 10% (6/60) all other drugs were successfully discontinued. No clear predictors of a reduction of other medications following initiation of sodium oxybate initiation could be identified. In five patients sodium oxybate was ineffective and discontinued.

6.2. Safety and tolerability

A total of 34 possible SEs associated with the administration of sodium oxybate were recorded from patients' medical records (Table 2). 55.6% (50/90) of our patients experienced a SE and in almost half of these cases (48%, 24/50) the drug had to be discontinued with subsequent resolution of the SE.

The most common SEs observed were nausea (17.7%), mood swings (15.5%) and enuresis (12.2%). One patient developed hypertension and three patients with known obstructive sleep apnea (OSA) required re-titration to higher continuous positive airway (CPAP) pressures despite no change in BMI or other clinical variables.

The SEs that led to drug discontinuation were viral infection, psychosis, suicidal ideation, mood swings, anxiety, headaches, impaired concentration, dizziness, unresponsiveness, nausea, vomit, diarrhea, faecal and urinary incontinence, gastroesophageal reflux disease, appetite loss, sweating, facial swelling, bad taste, pain, enuresis, worse cataplexy, hypertension and palpitations (11 patients experienced more than one SE). Among these the most common SEs resulting in drug discontinuation were nausea (25%), headaches (20.8%), mood swings (16.7%) and dizziness (16.7%). Psychosis as a serious limiting SE was identified in three patients, aged 51, 63 and 69 years old respectively, one of whom also exhibited suicidal ideation. These three patients underwent formal psychiatric assessment. None of these three patients had any previous relevant medical history or suffered from any other comorbidity. All three were on an anti-cataplectic agent, combined with desamphetamine in two of them and with modafinil in one another. Of note, psychotic symptoms resolved after discontinuation of sodium oxybate in all three patients.

No significant correlation between total SE incidence and age, BMI, gender and final dose of sodium oxybate prescribed was identified, but analysis of individual SEs demonstrated age to be associated with risk of psychosis (r = 0.234, p = 0.027) and enuresis (r = 0.251, p = 0.017), and BMI with dizziness and bad taste (r = 0.279, p = 0.021 and r = 0.257, p = 0.034 respectively). No statistically significant prediction model was generated using as the dependent variable any SE incidence and as independent variables age, BMI, gender, optimum dose of sodium oxybate prescribed, number of other concomitant drugs, reduction of other drug dosages, baseline ESS, and ΔESS (p = 0.333).

For these SEs resulting in discontinuation, time to drug discontinuation was added as an independent variable. Correlation analysis revealed that SEs resulting in drug discontinuation tended to occur early after the initiation of sodium oxybate, and thus at lower doses of the drug (r = −0.240, p = 0.027 and r = −0.482, p < 0.001 respectively). The time to drug discontinuation due to limiting SEs had a median 12 months (interquartile range 3.7–22.0). With regards to specific SEs that led to drug discontinuation, several correlations were found, amongst which age was again associated with psychosis (r = 0.238, p = 0.028) and enuresis (r = 0.252, p = 0.020) but also with headaches (r = 0.251, p = 0.017) and BMI with dizziness (r = 0.291, p = 0.021) and bad taste (r = 0.266, p = 0.035). When binary forward stepwise model analysis was performed aiming to predict the occurrence of any limiting SE using as independent variables the factors from the previous binary regression analysis (age, BMI, gender, optimum dose of sodium oxybate treated with sodium oxybate).

Table 2

| SE Type         | n (%) |
|-----------------|-------|
| General         |       |
| Amenorrhea      | 1 (1.1%) |
| Appetite loss   | 6 (6.6%) |
| Asthenia        | 1 (1.1%) |
| Bad taste       | 6 (6.6%) |
| Facial swelling | 1 (1.1%) |
| Pain            | 4 (4.4%) |
| Peripheral edema| 1 (1.1%) |
| Sweating        | 3 (3.3%) |
| Urinary incontinence | 2 (2.2%) |
| Psychiatric     |       |
| Anxiety         | 4 (4.4%) |
| Hallucinations  | 2 (2.2%) |
| Mood swings     | 14 (15.5%) |
| Psychosis       | 3 (3.3%) |
| Suicidal ideation| 1 (1.1%) |
| Cardiac         |       |
| Hypertension    | 1 (1.1%) |
| Palpitations    | 1 (1.1%) |
| Infections      |       |
| Viral infection | 1 (1.1%) |
| Gastrointestinal|      |
| Diarrhea        | 1 (1.1%) |
| Dry mouth       | 1 (1.1%) |
| Faecal incontinence | 1 (1.1%) |
| GERD            | 2 (2.2%) |
| Nausea          | 16 (17.7%) |
| Vomit           | 6 (6.6%) |
| Neurological    |       |
| Cramps          | 1 (1.1%) |
| Dizziness       | 9 (9.9%) |
| Headaches       | 7 (7.7%) |
| Impaired concent.| 6 (6.6%) |
| Myoclonus       | 1 (1.1%) |
| Unresponsiveness| 4 (4.4%) |
| Sleep disorders |       |
| Enuresis        | 11 (12.2%) |
| Insomnia        | 2 (2.2%) |
| Sleep walking   | 7 (7.7%) |
| Worse cataplexy | 1 (1.1%) |
| Worse OSA       | 3 (3.3%) |

GERD: gastroesophageal reflux disease, OSA: obstructive sleep apnea.
oxybate prescribed, number of other concomitant drugs, reduction of other drug dosages, baseline ESS and ΔESS) plus the time to drug discontinuation, increasing age (OR = 1.060, 95% CI = 1.004–1.119, p = 0.036) and shorter time to drug discontinuation (OR = 0.924, 95% CI = 0.886–0.963, p < 0.001) were both found to be associated with an increased likelihood of a limiting SE to occur.

7. Discussion

Few studies have explored the efficacy and safety of sodium oxybate outside the strictly regulated environment of a prospective controlled trial. Our cohort had 3116 patient-months of drug exposure, to our knowledge the highest exposure time described in the literature to date. These results support previous findings regarding the efficacy and safety of the drug [10,12,13,17–21]. It should be noted however that, owing to limitations of access to sodium oxybate in the United Kingdom, our cohort is likely to reflect a more severe or refractory phenotype than the cohorts in previous trials, with patients who have more severe EDS and more severe cataplexy, and who are refractory to traditional stimulants and anti-cataplectic agents.

The data presented highlight a number of salient points relevant to clinical practice. In this retrospective “real-life” analysis, sodium oxybate proved to be efficacious in terms of reduction observed in daytime sleepiness. Despite our patients having a higher baseline ESS, despite stimulant therapy, than in previous studies [10,12,13,19,22], the relative reduction in ESS observed in our study is comparable to those reported in the literature [10,12,13,19,21]. Furthermore, our data suggest that those patients who are sleepier or who have more severe cataplexy at baseline are the patients that would be expected to experience the most benefit. The impact of sodium oxybate on frequency of cataplexy events in our study was significant, but as expected, of a lower magnitude compared to other studies, since our cohort had already demonstrated itself to be refractory to traditional anti-cataplectic agents [10,13,22]. Whilst only 10% of patients achieved removal of other drugs for narcolepsy, approximately half of the patients that remained on sodium oxybate saw a lowering in their other drug dosages. The optimal maintenance dose could not be predicted by gender, BMI or other clinical factors.

In our cohort, a higher percentage of SEs leading to drug discontinuation was observed than in previous studies, perhaps reflecting the impact of co-administration of stimulants and anti-cataplectic agents, or the longer follow-up period. Over half of the patients (55.6%) experienced at least one SE, consistent with previous studies [17,19,21], but 26.6% were forced to stop the drug due to intolerable SEs. This is significantly higher than described in the literature (4.4%–9.4%) [10,13,17]. Again, this may be because our cohort consisted of patients with treatment refractory narcolepsy, with the majority already on other stimulants or/and anti-cataplectic agents. Additionally, a higher percentage of our patients received a higher optimized dose of 9 g/night (33%) than in other studies [10,13,17].

Nausea, mood swings and enuresis were the most frequent SEs, similar to, and at a comparable rate to, those reported in previous studies [10,13,17,19,21]. SEs did not appear to be dose-dependent or gender-related, but seemed more likely to occur in older patients, and were more likely to arise early in the treatment course and thus at lower doses. Our results also provide some indirect support to concerns that sodium oxybate may worsen sleep-disordered breathing, with three of our patients on CPAP requiring an increase in CPAP dose [23,24]. This stresses the need to remain vigilant for the development or exacerbation of OSA after the initiation of sodium oxybate, particularly as it is more common in patients with narcolepsy [25].

8. Limitations

Patients and data in this cohort were retrospectively identified and collected from our clinical records, providing a realistic snapshot of the efficacy and safety of sodium oxybate in clinical practice. While drawing this sample from a single institution signifies the utilisation of a consistent approach in data collection, a pre-established side effects list would have offered a more standardised assessment. As with all retrospective studies, data captured from the medical records are less reliable than prospective data entry. Prospective multi-centre studies would therefore add credence to our findings.

9. Conclusion

Sodium oxybate is an efficacious and generally safe treatment of patients with narcolepsy and cataplexy in standard clinical practice. Significant SEs that lead to drug withdrawal are more common in older patients and tend to occur early after initiation of the drug.

Disclosures

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Dr Drakatos reports no disclosures.
Dr Lykouras reports no disclosures.
Ms D’Ancona reports no disclosures.
Mr. Higgins reports no disclosures.
Dr Gildeh reports no disclosures.
Dr Macavei reports no disclosures.
Dr Rosenzweig reports no disclosures.
Dr Steier reports no disclosures.
Dr Muza reports no disclosures.
Prof. Williams reports previous fee from UCB Pharma as a speaker. Prof. Williams reports no conflicts of interest.
Dr Kent reports no disclosures.
Dr Leschziner reports speaker’s fees and honoraria for advisory boards from UCB Pharma. Dr Leschziner reports no conflicts of interest.

Authors’ contributorship statement

PD: Analysis, writing, design, interpretation, concept and discussion; DL: Data acquisition, analysis, writing; GD, SH, NG, RM, IR, JS, RM, AJW: Analysis, writing, interpretation and discussion, BDK, GL: Concept, analysis, writing, interpretation and discussion.

Acknowledgments

Dr Steier’s contribution was partially supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. Dr Rosenzweig is supported by the Wellcome Trust [103952/Z/14/Z]. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

Conflict of interest

The authors have no conflict of interest to declare regarding this study.
The ICMJE Uniform Disclosure Form for Potential Conflicts of Interest associated with this article can be viewed by clicking on the following link: http://dx.doi.org/10.1016/j.sleep.2017.03.028.

References

[1] Longstreth Jr WT, Koepsell TD, Ton TG, et al. The epidemiology of narcolepsy. Sleep 2007;30:13–26.
[2] Dauvilliers Y, Arnulf I, Mignot E. Narcolepsy with cataplexy. Lancet 2007;369:499–511.
[3] Billiard M, Bassetti C, Dauvilliers Y, et al. EFNS guidelines on management of narcolepsy. Eur J Neurol 2006;13:1035–48.
[4] Morgenthaler TI, Kapur VK, Brown T, et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep 2007;30:1705–11.
[5] Leschziner G. Narcolepsy: a clinical review. Pract Neurol 2014;14:323–31.
[6] Drakatos P, Leschziner GD. Update on hypersomnias of central origin. Curr Opin Pulm Med 2014;20:572–80.
[7] Dauvilliers Y, Montplaisir J, Molinari N, et al. Age at onset of narcolepsy in two large populations of patients in France and Quebec. Neurology 2001;57:2029–33.
[8] Maitre M. The gamma-hydroxybutyrate signalling system in brain: organization and functional implications. Prog Neurobiol 1997;51:337–61.
[9] Wise MS, Arand DL, Auger RR, et al. Treatment of narcolepsy and other hypersomnias of central origin. Sleep 2007;30:1712–27.
[10] Xyrem International Study Group. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 2002;25:42–9.
[11] Xyrem International Study Group. Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind, placebo-controlled study in 228 patients. Sleep Med 2005;6:415–21.
[12] Mamelak M, Black J, Montplaisir J, et al. A pilot study on the effects of sodium oxybate on sleep architecture and daytime alertness in narcolepsy. Sleep 2004;27:1327–34.
[13] Xyrem International Study Group. A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep 2003;26:31–5.
[14] American Academy of Sleep Medicine. International classification of sleep disorders. 2nd ed. Westchester, Illinois: American Academy of Sleep Medicine; 2005.
[15] Xyrem sodium oxybate product information, European Medicines Agency, download from http://www.ema.europa.eu, updated 08 September 2015.
[16] American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.
[17] Mamelak M, Swick T, Enslellm H, et al. 12-week open-label, multicenter study evaluating the safety and patient-reported efficacy of sodium oxybate in patients with narcolepsy and cataplexy. Sleep Med 2015;16:52–8.
[18] Xyrem International Study Group. Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med 2004;5:119–23.
[19] Black J, Swick T, Bogan R, et al. Impact of sodium oxybate, modafinil, and combination treatment on excessive daytime sleepiness in patients who have narcolepsy with or without cataplexy. Sleep Med 2016;24:57–62.
[20] Black J, Pardi D, Hornfeldt CS, et al. The nightly administration of sodium oxybate results in significant reduction in the nocturnal sleep disruption of patients with narcolepsy. Sleep Med 2009;10:829–35.
[21] Black J, Houghton WC. Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep 2006;29:939–46.
[22] Bogan RR, Roth T, Schwartz J, et al. Time to response with sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy. J Clin Sleep Med 2015;11:427–32.
[23] Seeck-Hirschner M, Baier PC, von Freier A, et al. Increase in sleep-related breathing disturbances after treatment with sodium oxybate in patients with narcolepsy and mild obstructive sleep apnea syndrome: two case reports. Sleep Med 2009;10:154–5.
[24] George CF, Feldman N, Inhaber N, et al. A safety trial of sodium oxybate in patients with obstructive sleep apnea: acute effects on sleep-disordered breathing. Sleep Med 2010;11:38–42.
[25] Chakravorty SS, Rye DB. Narcolepsy in the older adult: epidemiology, diagnosis and management. Drugs Aging 2003;20:361–76.